Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Gastrointestinal 1

Conditions

Postoperative Stage II/III Colon Cancer 1Chemotherapy-induced Peripheral Neuropathy 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ART123 × Clear all
NCT05251727 2024-08-19

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Veloxis Pharmaceuticals

Phase 1 Terminated
77 enrolled
Other

Chemotherapy-induced Peripheral Neuropathy

NCT02792842 2024-04-04

Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer

Asahi Kasei Therapeutics Corporation

Phase 2 Completed
79 enrolled 10 charts
Gastrointestinal

Postoperative Stage II/III Colon Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡